Published since 1959, International Review of Neurobiology is a well-known series appealing to neuroscientists, clinicians, psychologists, physiologists, and pharmacologists. Led by an internationally renowned editorial board, this important serial publishes both eclectic volumes made up of timely reviews and thematic volumes that focus on recent progress in a specific area of neurobiology research. In this volume, invited experts provide authoritative reviews on various aspects of Monoamine Oxidase and its Inhibitors.
1. Cover 2. Title Page 3. Table of Contents 4. Series Page 5. Copyright Page 6. CONTRIBUTORS 7. PREFACE 8. STRUCTURAL PROPERTIES OF HUMAN MONOAMINE OXIDASES A AND B 9. BEHAVIORAL OUTCOMES OF MONOAMINE OXIDASE DEFICIENCY: PRECLINICAL AND CLINICAL EVIDENCE 10. KINETIC BEHAVIOR AND REVERSIBLE INHIBITION OF MONOAMINE OXIDASES—ENZYMES THAT MANY WANT DEAD 11. THE PHARMACOLOGY OF SELEGILINE 12. TYPE A MONOAMINE OXIDASE REGULATES LIFE AND DEATH OF NEURONS IN NEURODEGENERATION AND NEUROPROTECTION 13. MULTIMODAL DRUGS AND THEIR FUTURE FOR ALZHEIMER’S AND PARKINSON’S DISEASE 14. NEUROPROTECTIVE PROFILE OF THE MULTITARGET DRUG RASAGILINE IN PARKINSON’S DISEASE 15. RASAGILINE IN PARKINSON’S DISEASE 16. SELECTIVE INHIBITORS OF MONOAMINE OXIDASE TYPE B AND THE “CHEESE EFFECT” 17. A NOVEL ANTI-ALZHEIMER’S DISEASE DRUG, LADOSTIGIL 18. NOVEL MAO-B INHIBITORS 19. Subject Index 20. Contents of recent volumes 21. Instructions for online access
Published since 1959, International Review of Neurobiology is a well-known series appealing to neuroscientists, clinicians, psychologists, physiologists, and pharmacologists. Led by an internationally renowned editorial board, this important serial publishes both eclectic volumes made up of timely reviews and thematic volumes that focus on recent progress in a specific area of neurobiology research. In this volume, invited experts provide authoritative reviews on various aspects of Monoamine Oxidase and its Inhibitors.
1. Cover 2. Title Page 3. Table of Contents 4. Series Page 5. Copyright Page 6. CONTRIBUTORS 7. PREFACE 8. STRUCTURAL PROPERTIES OF HUMAN MONOAMINE OXIDASES A AND B 9. BEHAVIORAL OUTCOMES OF MONOAMINE OXIDASE DEFICIENCY: PRECLINICAL AND CLINICAL EVIDENCE 10. KINETIC BEHAVIOR AND REVERSIBLE INHIBITION OF MONOAMINE OXIDASES—ENZYMES THAT MANY WANT DEAD 11. THE PHARMACOLOGY OF SELEGILINE 12. TYPE A MONOAMINE OXIDASE REGULATES LIFE AND DEATH OF NEURONS IN NEURODEGENERATION AND NEUROPROTECTION 13. MULTIMODAL DRUGS AND THEIR FUTURE FOR ALZHEIMER’S AND PARKINSON’S DISEASE 14. NEUROPROTECTIVE PROFILE OF THE MULTITARGET DRUG RASAGILINE IN PARKINSON’S DISEASE 15. RASAGILINE IN PARKINSON’S DISEASE 16. SELECTIVE INHIBITORS OF MONOAMINE OXIDASE TYPE B AND THE “CHEESE EFFECT” 17. A NOVEL ANTI-ALZHEIMER’S DISEASE DRUG, LADOSTIGIL 18. NOVEL MAO-B INHIBITORS 19. Subject Index 20. Contents of recent volumes 21. Instructions for online access
